On Tuesday, IAC/InterActiveCorp (NASDAQ:IACI)’s shares inclined 2.27%, and closed at $69.42, as HomeAdvisor is based in Golden, Colo., and is an operating business of IAC (IACI).
Almost half of homeowners put off home projects when they don’t have reliable cost information, according to HomeAdvisor’s 2015 True Cost Report*. The report provides insight into how cost influences homeowners’ approach to home projects, in addition to the struggles homeowners face in planning and budgeting for projects. The report, comprised of data presented to HomeAdvisor’s website and True Cost Guide, in addition to results from a recent survey* conducted among homeowners, also comprises an interactive infographic that compares costs for more than 50 home projects at the local and national level.
Highlights of the 2015 True Cost Report comprise:
- Two thirds of homeowners are concerned about overpaying for a home project, and more than one third of homeowners don’t know how much it will cost to hire a professional for home projects.
- The majority of homeowners paid for recent projects with accessible funds as opposed to financing.
- Homeowners plan to spend roughly the same amount on home projects in the forthcoming year as in the past year.
- Women are significantly more concerned about overpaying and finding a reliable cost source than men.
- Millennial homeowners, more than any other group, either put off a project when they don’t know how much it will cost or attempt to complete the project on their own.
- When asked to provide estimates for home projects, homeowners have a tendency to estimate that projects cost less than the actual cost.
IAC/InterActiveCorp operates as a media and Internet company in the United States and internationally. It operates through four segments: The Match Group, Search & Applications, Media, and eCommerce. The Match Group segment provides subscription-based and ad-supported online personals services through its Websites and applications.
Palo Alto Networks Inc (NYSE:PANW)’s shares raised 2.25%, and settled at $144.83, during the last trading session on Tuesday, soon after Palo Alto Networks (PANW), declared Palo Alto Networks AutoFocus cyber threat intelligence service, a new offering that provides precedingitized, actionable intelligence designed to give customers a clear advantage in the battle against cyber threats.
With the AutoFocus service, security practitioners gain instant access to actionable intelligence derived from billions of file analysis artifacts based on the files collected from of over 5,000 global enterprises, service providers, and government organization routinely targeted by advanced, targeted attacks. By delivering context, such as the origin and uniqueness of a particular threat, or relevance to an organization’s industry, the AutoFocus cyber threat intelligence service is able to:
- Expose the latest threat tactics, techniques, and procedures used by attackers;
- Attribute attacks to specific adversaries;
- Identify how specific threats fit into a larger campaign; and
- Distinguish between commodity malware as compared to highly customized or targeted malware.
Palo Alto Networks, Inc. provides enterprise security platform to enterprises, service providers, and government entities worldwide. Its platform comprises Next-Generation Firewall that delivers application, user, and content visibility and control, in addition to protection against network-based cyber threats; and Threat Intelligence Cloud that offers central intelligence capabilities, in addition to automated delivery of preventative measures against cyber attacks.
At the end of Tuesday’s trade, Peregrine Pharmaceuticals (NASDAQ:PPHM)’s shares picked up 2.22%, and closed at $1.38, soon after Peregrine Pharmaceuticals (PPHM), declared the peer-reviewed publication of clinical data from a Phase I investigator-sponsored trial evaluating the corporation’s lead investigational immunotherapy bavituximab plus paclitaxel therapy in patients with HER2-negative metastatic breast cancer. The manuscript details the results of the Phase I trial showing that the combination produced an objective tumor response in 85% of patients, counting 15% of these patients achieving a complete response, measured in accordance with Response Evaluation Criteria In Solid Tumors (RECIST) criteria.
“The publication of these data marks an important milestone in the development of this novel therapeutic in a difficult to treat patient population,” said Alison Stopeck, M.D., the principal investigator on the trial and Professor, Department of Medicine and Associate Director for Translational Research at the Stony Brook Cancer Center in Stony Brook, New York. “The regimen was very well tolerated and the clinical responses were encouraging. The data also suggest bavituximab may uniquely affect the coagulation system in a beneficial way for cancer patients. It is my belief that the combination of bavituximab with weekly paclitaxel is a feasible regimen that is associated with a promising response rate in patients with metastatic breast cancer and warrants further clinical exploration.”
Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in the research and development of novel monoclonal antibodies for the treatment and diagnosis of cancer in the United States. Its lead immunotherapy candidate, bavituximab, is in Phase III development for the treatment of second-line non-small cell lung cancer along with various investigator-sponsored trials evaluating other treatment combinations and additional oncology indications.
BioMarin Pharmaceutical Inc.(NASDAQ:BMRN), ended its Tuesday’s trading session with 2.01% gained, and closed at $121.17, soon after BioMarin Pharmaceutical ( BMRN), declared the results of a post-hoc sub-analysis of the PKU-016 or ASCEND study, the largest randomized controlled trial evaluating neurocognitive outcomes in patients with phenylketonuria (PKU) treated with the approved therapy Kuvan(R) (sapropterin dihydrochloride)at the 2015 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting. The sub-analysis comprised of 86 subjects 8 to 17 years of age with PKU who were randomized to blinded treatment with Kuvan (N = 43) or placebo (N = 43) for 13 weeks, after which all individuals received open label Kuvan for an additional 13 weeks.
This analysis evaluated the effects of Kuvan treatment on blood phenylalanine (Phe) concentration, attention deficit hyperactivity disorder-like symptoms, and executive function defects in children and adolescents with PKU. Symptoms of ADHD were evaluated by using the attention deficit hyperactivity rating scale (ADHD-RS) ordinaryly used to evaluate symptoms of inattentiveness and hyperactivity. There was a statistically noteworthydifference between the baseline and week 13 ADHD-RS total score with Kuvan contrast with placebo (p = 0.01).
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products comprise Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), an inherited metabolic disease; Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Firdapse, a form of 3,4-diaminopyridine used for the treatment of Lambert Myasthenic Syndrome, an autoimmune disease.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
